Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre

Haemophilia

Volumn 13, Issue 1, 2007, Pages 108-110

  Chuansumrit, Ampaiwan ^a   Husapadol, S ^a   Wongwerawattanakoon, P ^a   Hongeng, S ^a   Sirachainan, N ^a   Pakakasama, S ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

High inhibitor titre; Immune tolerance reduction; Rituximab (anti CD20); Severe haemophilia A

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; IMMUNOGLOBULIN G; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; TRANEXAMIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; ANAMNESIS; ARTICLE; BLEEDING; CASE REPORT; DISEASE DURATION; DRUG RESPONSE; HEMARTHROSIS; HEMATOMA; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; OPPORTUNISTIC INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; ISOANTIBODIES; MALE;

EID: 33845721790     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01407.x     Document Type: Article

References (5)

1. Hongeng S, Tardtong P, Worapongpaiboon S, Ungkanont A, Jootar S. Successful treatment of refractory autoimmune haemolytic anemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant 2002; 29: 871-2.
2. Mathia M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe hemophilia. Br J Haematol 2004; 125: 366-8.
3. Moschovi M, Aronis S, Trimis G, Platokouki H, Salavoura K, Tzortzatou-Stathopoulou F. Rituximab in the treatment of high responding inhibitors in severe haemophilia A. Haemophilia 2006; 12: 95-9.
4. Aggarwal A, Grewal R, Green RJ et al. Rituximab for autoimmune hemophilia: A proposed treatment algorithm. Haemophilia 2005; 11: 13-19.
5. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrate clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-64.